Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer
WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of
Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...
Pharmacyclics Announces Promising Results From Phase 2 Clinical
Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung
Cancer
- Data Support Rationale for Comprehensive Ongoing Phase 2 Programas Combination Agent with Standard Chemotherapies and Pivotal LungCancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpromising preliminary results from an open-label Phase 2 clinicaltrial of
Xcytrin(R) (motexafin gadoliniu...
Pharmacyclics Announces Presentations and Published Abstracts on
Xcytrin at The 2007 American Society of Clinical Oncology Annual
Meeting
SUNNYVALE, Calif., May 23, 2007 /PRNewswire-FirstCall/ --Pharmacyclics, Inc. announced today multiple presentations and apublished abstract regarding
Xcytrin(R) (motexafin gadolinium)Injection, including an oral presentation of Phase 3 SMART (Studyof Neurologic Progression with Motexafin Gadolinium And RadiationTherapy) trial data. The presentations and publications are part ofthe procee...